Boehringer Ingelheim permanently shelves production of clonidine, citing earlier recall and market competitors
One less version of clonidine, the decades-old blood pressure and ADHD drug, is now on the shelves.
Boehringer Ingelheim will discontinue its production of Catapres, telling the FDA the decision was due to both an October recall and a number of copycat drugs already on the market from other manufacturers.
BI, the German pharma giant, voluntarily recalled lots of three different doses of clonidine hydrochloride variant Catapres after an extraneous peak in a dissolution test, the company said at the time.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.